[Skip to Content]
[Skip to Content Landing]
JAMA Network Insights
June 2018

Management of Metastatic Melanoma in 2018

Author Affiliations
  • 1Department of Surgery, Massachusetts General Hospital, Boston
  • 2City of Hope, Duarte, California
  • 3Department of Medicine, Massachusetts General Hospital, Boston
JAMA Oncol. 2018;4(6):857-858. doi:10.1001/jamaoncol.2018.0170

In this Insights, we provide our perspective on rational treatment planning for patients with metastatic melanoma. Treatment planning should be individualized. Considerations include the extent and location of metastatic disease, tempo of disease progression, performance status, comorbidities with attention to underlying autoimmune disorders, and need for chronic immunosuppression and availability of clinical trials. Whenever possible, complete eradication of all metastatic disease should be the goal. Patients should be screened by history, physical examination, serum lactate dehydrogenase level, tumor BRAF mutation status, and complete body imaging, including central nervous system assessment. The Figure summarizes our current approach.